Literature DB >> 7808437

Site-directed mutagenesis of the peripheral benzodiazepine receptor: identification of amino acids implicated in the binding site of Ro5-4864.

R Farges1, E Joseph-Liauzun, D Shire, D Caput, G Le Fur, P Ferrara.   

Abstract

The peripheral benzodiazepine receptor (PBR) is an 18-kDa protein present in the outer mitochondrial membrane. The human PBR can be labeled with the benzodiazepine Ro5-4864 and with the isoquinoline carboxamide PK11195. The two ligands compete with each other in binding experiments, with previous results suggesting overlapping but not identical binding sites. To define the regions of the receptor interacting with PK11195 and Ro5-4864 and to address the question of the topology of the molecule in the membrane, we generated mutant human PBRs with amino- and carboxyl-terminal deletions and with point mutations in potentially accessible cytoplasmic regions. The mutant genes were expressed in yeast and analyzed in binding experiments using radiolabeled PK11195 and Ro5-4864. The results showed that, whereas deletions in the amino-terminal sequence had marked consequences for the binding affinity of both ligands, the final 13 amino acids at the carboxyl terminus could be deleted with no effect on the binding of either Ro5-4864 or PK11195. The site-directed mutagenesis experiments pinpointed four amino acids as participating in the binding site of Ro5-4864. Three of these, Glu-29, Arg-32, and Lys-39, which are located in the first putative cytoplasmic loop, are conserved in human, bovine, rat, and mouse PBRs. The remaining residue, Val-154, which is found at the interface between the putative fifth transmembrane region and the cytoplasm, is present in the human, rat, and mouse sequences but is replaced by methionine in the bovine sequence. The exchange of Met-154 for valine in the bovine PBR introduced a binding site for Ro5-4864, which is absent in the native PBR. These four amino acids played a minor role, if any, in the binding site of PK11195. We also showed that the histidines previously suggested to be part of the binding site of PK11195 are not directly involved in the interaction of the human receptor with either PK11195 or Ro5-4864.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7808437

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  18 in total

Review 1.  From simultaneous to synergistic MR-PET brain imaging: A review of hybrid MR-PET imaging methodologies.

Authors:  Zhaolin Chen; Sharna D Jamadar; Shenpeng Li; Francesco Sforazzini; Jakub Baran; Nicholas Ferris; Nadim Jon Shah; Gary F Egan
Journal:  Hum Brain Mapp       Date:  2018-08-04       Impact factor: 5.038

Review 2.  Translocator protein-mediated pharmacology of cholesterol transport and steroidogenesis.

Authors:  Vassilios Papadopoulos; Yasaman Aghazadeh; Jinjiang Fan; Enrico Campioli; Barry Zirkin; Andrew Midzak
Journal:  Mol Cell Endocrinol       Date:  2015-03-25       Impact factor: 4.102

3.  Protein structure. Crystal structures of translocator protein (TSPO) and mutant mimic of a human polymorphism.

Authors:  Fei Li; Jian Liu; Yi Zheng; R Michael Garavito; Shelagh Ferguson-Miller
Journal:  Science       Date:  2015-01-30       Impact factor: 47.728

4.  Development of a unique 3D interaction model of endogenous and synthetic peripheral benzodiazepine receptor ligands.

Authors:  N Cinone; H D Hötje; A Carotti
Journal:  J Comput Aided Mol Des       Date:  2000-11       Impact factor: 3.686

Review 5.  Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.

Authors:  Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 6.  Minireview: translocator protein (TSPO) and steroidogenesis: a reappraisal.

Authors:  Vimal Selvaraj; Douglas M Stocco; Lan N Tu
Journal:  Mol Endocrinol       Date:  2015-03-02

Review 7.  The changing landscape in translocator protein (TSPO) function.

Authors:  Vimal Selvaraj; Douglas M Stocco
Journal:  Trends Endocrinol Metab       Date:  2015-03-21       Impact factor: 12.015

Review 8.  Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers.

Authors:  Fabien Chauveau; Hervé Boutin; Nadja Van Camp; Frédéric Dollé; Bertrand Tavitian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10-01       Impact factor: 9.236

Review 9.  Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases.

Authors:  Md Maqusood Alam; Jihye Lee; Sang-Yoon Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-03-16

Review 10.  Insight into the Structural Features of TSPO: Implications for Drug Development.

Authors:  Jean-Jacques Lacapere; Luminita Duma; Stephanie Finet; Michael Kassiou; Vassilios Papadopoulos
Journal:  Trends Pharmacol Sci       Date:  2019-12-18       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.